Enterprise reports positive results from P2 trial

IP Group PLC

12 May 2026

 

FOR RELEASE ON

12 May 2026

Portfolio company Enterprise Therapeutics reports positive results
from Phase 2 clinical trial for cystic fibrosis

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and technology companies with the potential to create a better future for all, notes that portfolio company Enterprise Therapeutics Ltd ("Enterprise") has announced positive results from its Phase 2 trial for ETD001, its lead candidate for the treatment of cystic fibrosis.

The Phase 2 trial evaluated the efficacy, safety, tolerability and pharmacokinetics of inhaled ETD001 in the 10% of people with cystic fibrosis with the highest unmet medical need and achieved its primary efficacy outcome.

The data demonstrated a clinically meaningful improvement in lung function over a 28-day period compared to placebo. The results also showed that ETD001 is overall well-tolerated with adverse events consistent with those expected in this patient population.

Enterprise has outlined plans to advance ETD001 into longer‑duration Phase 2b studies and in combination with CFTR modulator therapies, which are effective for some but not all people with cystic fibrosis, and in other muco‑obstructive lung diseases where high unmet need remains.

Greg Smith, Chief Executive of IP Group, said: "This is a highly encouraging clinical milestone for Enterprise Therapeutics and a strong validation of its differentiated approach to cystic fibrosis. Demonstrating a clinically meaningful improvement in lung function in a population with significant unmet need highlights the potential of ETD001. For IP Group, this represents another example of our model providing investors with access to differentiated deep science opportunities."

For more information, please contact:

IP Group plc	www.ipgroupplc.com
Liz Vaughan-Adams, Communications	[phone]/[phone]
Portland
Lewis Bendall-Craft	[phone]

Notes for editors

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com.

ENDS

 

END